SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Wednesday reported first-quarter net income of $244.5 million. The Silver Spring, Maryland-based company said it had profit of $5.57 per share. Earnings, adjusted for stock …
Prof. Christopher Patusky, J.D. is Lead Independent Vice Chairman of the Board of the Company. He has more than 25 years of experience in the private, public and nonprofit sectors. After graduating from The Harvard Law School, he …
In 1Q18, United Therapeutics’ (UTHR) Remodulin generated revenues of $127 million compared to $145.8 million in 1Q17. That was a 13% decline YoY (year-over-year) and a 30% decline quarter-over-quarter.
Prof. Katherine J. Klein, Ph.D. is Independent Director of the Company. She has served as the Vice Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put United Therapeutics Corporation UTHR stock into this equation and find out if it …